Forest Lexapro “Not Approvable” For Panic Disorder Again
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA issues second “not approvable” letter for the selective serotonin reuptake inhibitor. Forest is reviewing FDA’s response and has not yet determined the appropriate next step.